Global Gene Therapy for Inherited Genetic Disorders Market 2019-2023

#Snapshot img { margin: 10px !important; } Some of the key findings from our gene therapy for inherited genetic disorders market forecast report are summarized belowSee the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.Get a FREE sample now!Global gene therapy market for inherited genetic disorders: Industry overviewGene therapy has the potential to cure inherited diseases that cannot be cured using conventional drugs. It is being increasingly adopted in clinical trials because of its high efficacy and safety towards the treatment of inherited genetic disorders. For instance, LUXTURNA, an AAV-based gene therapy is used for the treatment of biallelic RPE65 mutation associated retinal dystrophy. Similarly, Strimvelis, an ex vivo stem cell gene therapy is indicated as a single treatment for patients with ADA-severe combined immunodeficiency. The high efficacy and safety offered by gene therapy will increase the preference for gene therapy treatments for inherited genetic disorders, subsequently driving gene therapy for inherited genetic disorders market growth during the forecast period.Additionally, upcoming gene therapy for inherited genetic disorders market trends such as the increase in strategic alliances among vendors will also influence the growth of this global market. Vendors in this market are focusing on entering into partnerships to capitalize on the growing demand for curative gene therapies. Merck KGaA and GenScript Biotech Corp. recently formed an alliance to focus on the manufacturing of plasmid and viral vector in China. Many such alliances among vendors will result in the development of novel gene therapies for patients with inherited genetic disorders. As a result of these factors, the global gene therapy for inherited genetic disorders market size will grow at a CAGR of 189%. However, the market’s momentum will decelerate in the coming years because of the decrease in year-over-year growth.Top gene therapy companies for inherited genetic disorders covered in this market research reportThe global gene therapy for inherited genetic disorders market is highly concentrated. This research report provides a detailed analysis of the market’s competitive landscape and provides information on the products offered by various companies. Key insights provided by this gene therapy for inherited genetic disorders market report will help companies create effective strategies to improve their revenue share.The report offers a detailed analysis of several leading companies including:BioMarin Pharmaceutical Inc.bluebird bio Inc.Novartis AGOrchard Therapeutics PlcSpark Therapeutics Inc.Gene therapy for inherited genetic disorders market segmentation based on applicationEye disordersHematological disordersCentral nervous system disordersMuscular disordersOthersGene therapy was mainly adopted for the treatment of genetic eye disorders in 2018. With the increasing prevalence of hematological disorders across the world, the adoption of gene therapy will increase in hematological disorders applications and this segment will account for the largest market share by the end of the forecast period.Gene therapy for inherited genetic disorders market segmentation based on geographyAsiaEuropeNorth AmericaROWNorth America will provide maximum growth opportunities for companies in the gene therapy for inherited genetic disorders market. Vendors in the region are developing drugs for inherited genetic disorders that are in the final stages of clinical trials and are expected to be launched during the forecast period. This coupled with the availability of installment-based reimbursement model will contribute to the growth of gene therapy for inherited genetic disorders market growth in North America.Key highlights of the global gene therapy for inherited genetic disorders market for the forecast period 2019-2023CAGR of the market during the forecast period 2019-2023Detailed information on factors that will accelerate the growth of the gene therapy for inherited genetic disorders market during the next five yearsPrecise estimation of the global gene therapy for inherited genetic disorders market size and its contribution to the parent marketAccurate predictions on upcoming trends and changes in consumer behaviorThe growth of the gene therapy for inherited genetic disorders industry across Asia, Europe, North America, and ROWA thorough analysis of the market’s competitive landscape and detailed information on several vendorsComprehensive details of factors that will challenge the growth of gene therapy companies for inherited genetic disorders We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

基因治疗市场对遗传性遗传疾病的预测报告的关键发现概述如下。详见完整的目录和展示列表，以及本报告精选的插图和示例页面。立即获取免费样本！全球遗传性遗传疾病基因治疗市场：行业概览基因治疗具有治愈传统药物无法治愈的遗传性疾病的能力。由于其针对遗传性遗传疾病治疗的高效性和安全性，基因治疗在临床试验中得到越来越多的应用。例如，LUXTURNA，一种基于AAV的基因治疗药物，用于治疗双等位基因RPE65突变相关的视网膜营养不良。同样，Strimvelis，一种体外干细胞基因治疗，被指定为ADA严重联合免疫缺陷患者的单一治疗方案。基因治疗提供的卓越疗效和安全性将增加对遗传性遗传疾病基因治疗方案的偏好，从而推动预测期内基因治疗市场增长。此外，即将到来的遗传性遗传疾病基因治疗市场趋势，如供应商之间战略联盟的增加，也将影响全球市场的增长。该市场的供应商正致力于建立伙伴关系，以利用治愈性基因疗法的日益增长的需求。默克KGaA和GenScript生物科技公司最近结成联盟，专注于在中国制造质粒和病毒载体。众多此类供应商之间的联盟将导致为患有遗传性遗传疾病的患者开发新型基因治疗药物。因此，全球遗传性遗传疾病基因治疗市场规模将以189%的复合年增长率增长。然而，由于年度增长率下降，市场动力将在未来几年放缓。本市场研究报告涵盖的全球遗传性遗传疾病基因治疗领域的领先基因治疗公司包括：BioMarin制药公司bluebird bio公司诺华AGOrchard治疗学公司Spark治疗学公司遗传性遗传疾病基因治疗市场按应用细分眼疾血液疾病中枢神经系统疾病肌肉疾病其他2018年，基因治疗主要用于治疗遗传性眼科疾病。随着全球血液疾病发病率的增加，基因治疗在血液疾病领域的应用将增加，并在预测期末占据最大的市场份额。北美将为遗传性遗传疾病基因治疗市场的公司提供最大的增长机会。该地区的供应商正在开发处于临床试验终末阶段的遗传性遗传疾病药物，并预计将在预测期内上市。这加上基于分期付款的报销模式，将有助于推动北美遗传性遗传疾病基因治疗市场的增长。预测期内全球遗传性遗传疾病基因治疗市场的关键亮点市场在预测期（2019-2023年）的复合年增长率详细关于将加速遗传性遗传疾病基因治疗市场在未来五年增长的因素的详细信息全球遗传性遗传疾病基因治疗市场规模的精确估计及其对母市场的贡献对即将到来的趋势和消费者行为变化的准确预测亚洲、欧洲、北美和ROW遗传性遗传疾病基因治疗行业的增长全球市场的竞争格局的详细分析以及关于几个供应商的详细信息挑战遗传性遗传疾病基因治疗公司增长的因素的全面细节我们能够提供帮助！我们的分析师可以定制本市场研究报告以满足您的需求。请联系我们。